Drug Detail

Information about INBRX-109

Generic Name
IND	INBRX-109
Brand Name (US)
Manufacturer	Inhibrx, Inc.
Drug Type	DR5 agonist
Delivery	Intravenous
Approval Status	Phase 2
Indications
Overall Strategy	GIST cell based
Strategy	Activate Death Receptor
Drug Category	SDH-directed

The FDA has granted an orphan drug designation to INBRX-109 for the treatment of chondrosarcoma, according to a press release by Inhibrx, Inc.1

INBRX-109 is a tetravalent death receptor 5 (DR5) agonist antibody that is meant to leverage tumor-biased cell death caused by DR5 activation.and avoid apoptosis of normal cells.